December 5, 2023

IntegriChain and Blue Fin Group Pharma Trade and Distribution Experts to Speak at Informa Trade & Channel Strategies

Philadelphia, PA, December 5, 2022 – IntegriChain, delivering pharma’s only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, today announced that pharmaceutical strategy expert Bill Roth, General Manager and Managing Partner, Blue Fin Group, an IntegriChain Company, will be the keynote speaker at Informa’s Trade & Channel Strategies conference. In addition, distribution experts David Weiss, IntegriChain Vice President of Industry Solutions, and Jason Bogroff, Blue Fin Group Partner, will speak at the event. IntegriChain is a sponsor of the conference, which runs December 11 through 13 in Philadelphia.

Details of the highlighted sessions are as follows.

Monday, December 11, 2023

Keynote: The Economics of the Pharmacy and Distribution Channel
8:45 am ET
Bill Roth

In this keynote address, Roth will explore key insights on the pulse of the industry and what is seen as areas of focus of the future, including:

  • Economics for Access and Channel impacting new challenges with commercialization
  • Residual impact of the Generic Patent Cliff and how it’s impacting PBMs, Retailers, Wholesalers and GPOs
  • Early glimpses at the Specialty Patent Cliff and a check-in on Pharmacy Benefit Biosimilars
  • Mix of direct and indirect distribution across the product archetypes and why direct is growing
  • Why Retailers aren’t making money on brands and are asking pharmaceutical manufacturers to bail them out
  • Growth of cash pay and what that means for Access and Channel

Partnership Pavilion Panel
2:15 pm ET
Jason Bogroff, Moderator
Jeff Henderson, Vice President, Head of Global Market Access, Reimbursement and Distribution, VectivBio
Eliane Maalouf, Director of Trade and Fulfillment – Specialty Pharmacy, Mass General Brigham
John Robicsek, Assistant Vice President, Strategy, Business, and Program Development, Atrium Health

In this session, the stakeholders of the channel, including 3PL, Distribution, Pharmacy, and Manufacturers will explore areas that the industry can come together, what is needed moving forward, and opinions on overall trends in the marketplace.

Tuesday, December 12, 2023

Innovative Distribution Models – What Are the Alternative Paths to the Patients?
11:45 am ET
Dave Weiss

In this session, Weiss will explore how manufacturers can identify new pathways and channels in the marketplace. He’ll review the growth in Generics and why pharmacies are going out of business. He also will discuss how manufacturers can gain insight on the state of direct pharmacies and evaluate if it is beneficial for a given product to return to this method.

About ICyte Data Solutions
IntegriChain offers a full suite of channel data products, including:

Channel Data Solutions: Data aggregation and refinement solutions unite data sets from sales, inventory, specialty pharmacy inventory, and product returns channels while leveraging industry-leading data science and enrichment algorithms to deliver an end-to-end view of distribution. Aggregation of all channel and distribution datasets including ExFactory Sales, Distributor Inventories, Demand, and Returns deliver the highest quality master data to provide better data and better insights.  

Inventory Analytics: Manufacturers have few existing measures of the inventory held in retail stores, distribution centers, and third-party returns processors. ICyte Inventory Analytics reports 100% of inventory in the retail channel, even in pharmacy stores and distribution centers that do not report their inventories.

Distribution Contract Management: Distribution Contract Management is a SaaS-based, market-proven application for managing all aspects of trade partner agreements. Configurable trade partner scorecard functionality features payment adjudication, custom pay-for-performance metrics, payment roll forward, and top- and bottom-line functionality adjustments. 

Channel Data Consulting Services: Based on IntegriChain pioneering the field of channel data aggregation, stewardship, and advanced analytics, the company’s consulting services deliver Market Demand Analysis, Class of Trade, Downstream Inventory Analytics, Returns Forecasting, and Revenue Analytics to Pharma manufacturers of all types and sizes.

About IntegriChain
IntegriChain helps pharma manufacturers bring their science to market, ensuring patients have affordable, timely, and sustainable access to therapy. IntegriChain delivers Pharma’s only data-driven commercialization platform — from strategy to operational execution. The Company’s unique focus on data, technology, consulting, and outsourcing helps connect the commercial, financial, and operational dimensions of drug access and profitability. Through the ICyte Platform, IntegriChain enables pharmaceutical innovators to achieve better commercial outcomes by digitalizing daily and recurring business activities and by integrating data and operations across contracting, pricing, channel and distribution, and gross-to-net. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm, and is headquartered in Philadelphia, PA, with offices in Ambler, PA, and Pune, India. For more information, visit or follow on LinkedIn.

About Blue Fin Group, an IntegriChain Company
Blue Fin Group develops strategies to optimize patient access, commercialization, and gross-to-net to support life sciences manufacturers throughout the product life cycle. Blue Fin Group is a full-service management consulting firm delivering research, strategy, and implementation to help manufacturers align all the elements of marketing, market access, field sales, pharmacy and distribution, and patient services as a seamless commercial strategy that helps optimize patient outcomes. Blue Fin Group has served more than 300 manufacturers–primarily those commercializing their first asset or large global firms with products that span cell and gene therapies, orphan/rare, specialty, primary care, vaccines, biosimilars, and generics. For additional information, visit or follow on Twitter bluefingroup and LinkedIn.

Jennifer Guinan, Sage Strategic Marketing, 610.410.8111,

adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand paper article